Cost-effectiveness of posaconazole versusfluconazole or itraconazole in the prevention of invasive fungal infections among high-risk neutropenic patients in Spain

Table 3 Results of the base case of posaconazole versus SAT in the prevention of IFI among high-risk neutropenic patients

Strategy	Total costs*	IFI events	LYS	ICER (cost per IFI avoided)	ICER (cost per LYS)
Posaconazole	6,121	0.05	2.52
SAT	7,928	0.11	2.43
Difference^†	-1,807	-0.06	0.09	Dominant^‡	Dominant^‡

*In euros at November 2009 prices
^†Difference between posaconazole and SAT
^‡Dominant strategy: posaconazole has lower cost and higher efficacy (measured as IFI avoided and LYS) compared to SAT (standard azole treatment: fluconazole 81% patients/itraconazole 19% patients)

ISSN: 1471-2334